RecruitingB-cell Non Hodgkin LymphomaChronic Lymphocytic Leukemia

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Sponsor: Medical University of South Carolina

You may qualify if…

✓ Patients eligible for study participation must meet all of the following criteria:
✓ 1. Disease Related Criteria
✓ Participants must have histologic confirmation of one of the following:
✓ 1. CD19+ aggressive non-Hodgkin lymphoma including any of the following subtypes
✓ Diffuse Large B-cell Lymphoma, not otherwise specified
✓ DLBCL, germinal-center B-cell type (GCB)
✓ DLBCL, activated B-cell type (ABC)
✓ T-cell histiocyte-rich B-cell lymphomas (THRBCL)

You may not qualify if…

✕ Participants eligible for study participation CANNOT meet any of the following criteria:
✕ 1. Prior/Concurrent Therapy Related Criteria Guidelines regarding when lymphoma directed therapy should be stopped prior to leukapheresis, lymphodepleting chemotherapy, and CAR T-cell infusion are detailed in the protocol. These criteria must be planned to be met for all patients.
✕ 2. Clinical/Laboratory Criteria
✕ 1. Women who are pregnant or breast-feeding.
✕ 2. Participants with active CNS lymphoma. Participants can have a history of active CNS lymphoma as outline in protocol
✕ 3. Participants with evidence of Graft vs Host Disease from allogeneic stem cell transplant are ineligible unless it is either grade 1 involvement of the skin or not requiring systemic immunosuppression.
✕ 4. Participants with uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
✕ 5. Participants with a history of stroke or intracranial hemorrhage within 6 months prior to registration. Any CNS disorder that would serve as a major barrier in evaluating neurotoxicity/ICANS per enrolling physician

Where it's recruiting

South Carolina

Charleston

Source: ClinicalTrials.gov · NCT05702853 · last updated 2026-03-27